Merck's Keytruda has generated unprecedented sales of $29.5 billion, surpassing the previous record held by Abbvie’s Humira. This monoclonal antibody, approved for various cancers, challenges healthcare funding structures globally. Its significant sales reflect not just financial success but also a shift in treatment paradigms, as public health systems struggle to accommodate such costly therapies. Keytruda's development history, once deemed a low priority, demonstrates the complexity of pharmaceutical advancements, paving the way for changing cancer care and public health policies.
Keytruda's unprecedented sales of $29.5 billion highlight a paradigm shift in pharmaceutical funding, as it surpasses previous records and transforms public health treatment approaches.
Merck's Keytruda has achieved $29.5 billion in sales, reshaping perceptions of cancer treatments and public funding, challenging healthcare systems worldwide to adapt.
The rise of Keytruda, with 30 EMA-approved indications, exemplifies a remarkable evolution in cancer therapy, showcasing its critical role in modern medical treatment.
Keytruda represents a significant breakthrough, having gone from potential abandonment in 2017 to becoming a top-selling drug, emphasizing urgent changes in drug funding and access.
Collection
[
|
...
]